◀ Back to PTBP1

PTBP1 — VIP

Text-mined interactions from Literome

Gonzalez-Rey et al., Blood 2006 : We here report that the immunosuppressive neuropeptide vasoactive intestinal peptide (VIP) induces the generation of human tolerogenic DCs with the capacity to generate CD4 and CD8 T ( reg ) cells from their respective naive subsets
Chorny et al., Blood 2006 (Acute Disease...) : VIP induced tolerogenic DCs did not abrogate the graft-versus-leukemia response presumably by not affecting the cytotoxicity of transplanted T cells against the leukemic cells ... Therefore, the inclusion of VIP induced tolerogenic DCs in future therapeutic regimens may minimize the dependence on nonspecific immunosuppressive drugs used currently as antirejection therapy, and facilitate the successful transplantation from mismatched donors, by reducing the deleterious consequences of acute GVHD and extending the applicability of BMT
Delgado et al., Ann N Y Acad Sci 2006 (Acute Disease...) : Importantly, VIP induced tolerogenic DCs did not abrogate the graft versus leukemia response, probably because they do not abrogate cytotoxicity of transplanted T cells against the leukemic cells
Weng et al., J Neuroimmunol 2007 : It was reported that VIP can induce regulatory dendritic cells (DCs) and promote Th2-type responses
Chorny et al., Ann N Y Acad Sci 2006 (Autoimmune Diseases) : In contrast, VIP reduces both CD86 and CD80 expression on lipopolysaccharide (LPS) stimulated DCs, and inhibits the capacity of DCs to induce in vitro or in vivo T cell proliferation ... However, addition of VIP in the early states of DC differentiation results in the generation of DCs that can not mature following inflammatory stimuli that exhibit a tolerogenic phenotype, characterized by low expression of costimulatory molecules ( CD40, CD80, and CD86 ), low production of proinflammatory cytokines, increased production of IL-10, and capacity to induce regulatory T cells with suppressive actions